The Glucagon-Like Peptide-1 Receptor (GLP-1R) is a critical target for obesity research and drug discovery, with functional bioassays serving as essential tools for evaluating therapeutic potential. Semaglutide, a leading obesity research tool and breakthrough GLP-1 receptor agonist achieving 15-19% weight loss, represents the gold standard for metabolic therapeutics development.
This bioassay kit serves pharmaceutical companies developing GLP-1 receptor agonist therapies for diabetes, obesity, and cardiovascular disease. Applications include drug characterization, lot release testing, stability studies, and neutralizing antibody screening. The ready-to-use format accelerates results.
Eurofins DiscoverX's qualified kit has been optimized with Ozempic® to meet regulatory requirements, providing validated parameters including 97% accuracy, 8.7% repeatability, and 8.5% intermediate precision.